Construction and application evaluation of molecular model for predicting postoperative early recurrence risk of liver cancer
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
- Publication Date
- 2019-12-17
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the field of medical biological detection, in particular to the construction of a molecular model for predicting the early recurrence risk after liver cancer surgery and its application evaluation. Background technique
[0002] Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the second leading cause of cancer-related death worldwide. At present, the diagnosis and operation techniques of liver cancer have gradually matured, but there are still a large number of patients with liver cancer who frequently relapse after surgery and further progress to advanced liver cancer, which ultimately leads to a poor overall prognosis of liver cancer. As we all know, the recurrence of liver cancer is divided into two types: early recurrence and late recurrence based on the 2 years after operation. Early recurrence is considered as "true recurrence", accounting for more than 70% of liver cancer recurrence, which leads...